Visit the Emblem Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Emblem Sees Significant Rise in Patient Acquisition
PARIS, ONTARIO–(Marketwired – March 20, 2017) –
Emblem Corp. (TSXV: EMC) (OTC: EMMBF) (“Emblem” or the “Company”) is pleased to announce that the Company has successfully ramped up its patient acquisition program resulting in a total of 2,091 active and pending patients (net of expired and disabled registrations) having registered since the opening of its patient fulfillment website in late November, 2016. Patient acquisition has been progressively accelerating with 49 patients registered in November, 157 in December, 437 in January, 691 in February and 553 in March to date with a further 246 registrations pending verification.
We are extremely pleased with the progress made since the launch of our website to attract and register patients at such an accelerated rate. We believe that our patient growth is a favorable reflection on the quality of our cannabis products, our customer service and our physician and patient communication strategies.
Gordon Fox, CEO of Emblem Corp.
Emblem is also pleased to report that GrowWise Health, Emblem’s cannabis healthcare vertical, is continuing to expand its clinic network. “GrowWise clinics and cannabis education centres promise to become an important source of patients for Emblem,” says Fox.
With physicians becoming more comfortable referring patients and embracing cannabis as an alternative treatment, GrowWise is quickly expanding its presence across Canada. Thus far in 2017, four new GrowWise locations have opened their doors to patients across Ontario and in British Columbia, bringing the total to 11 clinics, with more locations scheduled to open across the country in the coming months.
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) through its wholly owned subsidiary, Emblem Cannabis Corporation, to cultivate and sell medical cannabis. Emblem carries out its principal activities producing cannabis from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.
The most reliable, fact-based information on Emblem Corp found only on its Investor Dashboard.
Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.